This is not the most recent version of the article. View current version (18 JUN 2013)

Intervention Protocol

Interferon alpha for the adjuvant treatment of cutaneous melanoma

  1. Simone Mocellin1,*,
  2. Marko B Lens2,
  3. Sandro Pasquali1,
  4. Pierluigi Pilati1

Editorial Group: Cochrane Skin Group

Published Online: 19 JAN 2011

DOI: 10.1002/14651858.CD008955


How to Cite

Mocellin S, Lens MB, Pasquali S, Pilati P. Interferon alpha for the adjuvant treatment of cutaneous melanoma (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD008955. DOI: 10.1002/14651858.CD008955.

Author Information

  1. 1

    University of Padova, Department of Oncological & Surgical Sciences, Padova, Veneto, Italy

  2. 2

    King's College, Genetic Epidemiology Unit, London, UK

*Simone Mocellin, Department of Oncological & Surgical Sciences, University of Padova, Via Giustiniani 2, Padova, Veneto, 35128, Italy. simone.mocellin@unipd.it. mocellins@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 19 JAN 2011

SEARCH

This is not the most recent version of the article. View current version (18 JUN 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the disease-free survival and overall survival effects of interferon alpha as adjuvant treatment for people with high-risk cutaneous melanoma. Adverse events and quality of life, even if they represent a crucial issue in interferon alpha treatment, will not be addressed in the present study, as virtually all trials have compared interferon treatment with observation (i.e. no treatment).